BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bexicaserin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bexicaserin\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06660394-8867@assetmemo.bio
DTSTAMP:20261121T005439Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06660394)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Phase 3\, Placebo-C
 ontrolled Study to Investigate LP352 in Children and Adults With Dravet Sy
 ndrome (DS)\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06660394
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908226-8867@assetmemo.bio
DTSTAMP:20261121T005439Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06908226)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Study to Investigat
 e LP352 in Children and Adults With Developmental and Epileptic Encephalop
 athy (DEE)\nEstimated primary completion: 11 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06908226
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
